SIMILAR PATTERNS OF AMINO ACIDS FOR 5AAA_A_VGHA9000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.65A	5aaaA-1k9aA: 32.9	5aaaA-1k9aA: 25.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	VAL A 588 ALA A 606 MET A 657 GLY A 660 LEU A 731 ASP A 742	None	0.67A	5aaaA-1lufA: 33.1	5aaaA-1lufA: 35.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.56A	5aaaA-1opkA: 31.0	5aaaA-1opkA: 26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 78 VAL A 86 ALA A 99 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.49A	5aaaA-1s9iA: 22.1	5aaaA-1s9iA: 25.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 344 VAL A 352 ALA A 367 GLY A 420 LEU A 468 ASP A 479	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) STU A 100 (-3.5A) STU A 100 (-4.5A) STU A 100 (-3.5A)	0.78A	5aaaA-1u59A: 32.3	5aaaA-1u59A: 33.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 GLY A 110 LEU A 158 GLY A 168 ASP A 169	None	0.72A	5aaaA-1u5qA: 25.5	5aaaA-1u5qA: 29.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LEU A 84 GLY A 90 LEU A 137 ASP A 148	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-4.2A) None HYM A 400 (-4.5A) HYM A 400 (-3.9A)	0.85A	5aaaA-1zltA: 21.3	5aaaA-1zltA: 24.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 26 VAL A 34 ALA A 47 LEU A 98 GLY A 104 LEU A 155 ASP A 166	STU A1301 (-4.2A) STU A1301 (-4.8A) STU A1301 (-3.6A) STU A1301 ( 4.7A) STU A1301 ( 4.0A) STU A1301 ( 4.8A) None	0.69A	5aaaA-2bujA: 23.9	5aaaA-2bujA: 25.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 MET X 85 GLY X 88 LEU X 137 ASP X 148	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 (-3.6A)	0.70A	5aaaA-2dq7X: 31.9	5aaaA-2dq7X: 37.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 ALA A 40 MET A 96 LEU A 144 ASP A 155	ADP A 500 (-4.3A) ADP A 500 (-4.3A) ADP A 500 ( 3.7A) None ADP A 500 (-4.3A) ADP A 500 ( 2.9A)	0.76A	5aaaA-2f9gA: 22.6	5aaaA-2f9gA: 23.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 GLY A 110 LEU A 158 GLY A 168 ASP A 169	STU A 400 ( 4.8A) STU A 400 (-3.2A) STU A 400 (-3.4A) STU A 400 ( 4.6A) None STU A 400 (-3.6A)	0.66A	5aaaA-2gcdA: 26.4	5aaaA-2gcdA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ASP A 404	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 (-4.2A)	0.63A	5aaaA-2h8hA: 30.4	5aaaA-2h8hA: 22.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.58A	5aaaA-2hckA: 29.5	5aaaA-2hckA: 26.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 ALA A 271 MET A 319 GLY A 322 LEU A 371 ASP A 382	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A) 1BM A 499 (-4.4A)	0.52A	5aaaA-2hk5A: 24.1	5aaaA-2hk5A: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 248 VAL A 256 ALA A 269 MET A 318 GLY A 321 LEU A 370 ASP A 381	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) None None GIN A 600 (-4.7A) GIN A 600 (-4.9A)	0.80A	5aaaA-2hz0A: 31.1	5aaaA-2hz0A: 37.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	6	VAL A 436 ALA A 452 GLY A 505 LEU A 553 GLY A 563 ASP A 564	4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 (-3.2A) 4ST A1687 (-4.4A) None 4ST A1687 (-4.7A)	0.69A	5aaaA-2j0jA: 33.1	5aaaA-2j0jA: 19.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 251 VAL A 259 ALA A 271 MET A 319 GLY A 322 LEU A 371	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.69A	5aaaA-2og8A: 30.4	5aaaA-2og8A: 40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 VAL A 596 ALA A 614 GLY A 669 LEU A 785 GLY A 795 ASP A 796	None	0.79A	5aaaA-2ogvA: 30.9	5aaaA-2ogvA: 36.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	LEU A 25 VAL A 33 ALA A 46 MET A 106 GLY A 109 LEU A 156 ASP A 167	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None ATP A 381 ( 4.8A) MN A 382 (-2.0A)	0.66A	5aaaA-2phkA: 23.0	5aaaA-2phkA: 23.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pmi	CYCLIN-DEPENDENT PROTEIN KINASE PHO85 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	VAL A 21 ALA A 34 MET A 85 LEU A 140 GLY A 150 ASP A 151	AGS A3001 (-4.4A) AGS A3001 (-3.5A) None None None AGS A3001 (-2.8A)	0.70A	5aaaA-2pmiA: 15.1	5aaaA-2pmiA: 25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	VAL B 55 ALA B 67 MET B 117 GLY B 120 LEU B 171 ASP B 182	None	0.51A	5aaaA-2qkwB: 24.6	5aaaA-2qkwB: 27.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 MET A 702 GLY A 705 LEU A 753 ASP A 764	BME A 1 (-4.9A) PTR A 701 ( 4.7A) PTR A 701 ( 3.5A) None None None	0.49A	5aaaA-2qobA: 34.5	5aaaA-2qobA: 33.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 689 ALA A 705 MET A 756 GLY A 759 LEU A 807 ASP A 818	None	0.33A	5aaaA-2r2pA: 34.6	5aaaA-2r2pA: 33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 VAL A 732 ALA A 749 MET A 799 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.49A	5aaaA-2r4bA: 30.5	5aaaA-2r4bA: 32.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 226 VAL A 234 ALA A 247 LEU A 301 MET A 304 GLY A 307 LEU A 354	XK9 A1511 (-3.8A) XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.6A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A)	0.76A	5aaaA-2xk9A: 21.6	5aaaA-2xk9A: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 234 ALA A 247 LEU A 301 MET A 304 GLY A 307 LEU A 354 ASP A 368	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.6A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A) XK9 A1511 (-3.6A)	0.84A	5aaaA-2xk9A: 21.6	5aaaA-2xk9A: 25.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 MET A 702 GLY A 705 LEU A 753 ASP A 764	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A) None	0.67A	5aaaA-2xyuA: 26.4	5aaaA-2xyuA: 34.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 68 VAL A 76 ALA A 92 LEU A 141 GLY A 147 LEU A 194 ASP A 205	STU A 1 (-3.8A) None STU A 1 (-3.3A) STU A 1 ( 4.6A) STU A 1 ( 3.9A) STU A 1 (-4.6A) STU A 1 ( 3.8A)	0.83A	5aaaA-2z7rA: 21.8	5aaaA-2z7rA: 24.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1002 VAL A1010 ALA A1028 MET A1079 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None None	0.47A	5aaaA-2z8cA: 30.5	5aaaA-2z8cA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 253 VAL A 261 ALA A 273 MET A 322 GLY A 325 LEU A 374 ASP A 385	None	0.54A	5aaaA-2zv7A: 32.8	5aaaA-2zv7A: 35.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.65A	5aaaA-3d7uA: 26.3	5aaaA-3d7uA: 34.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 431 VAL A 439 ALA A 455 GLY A 508 LEU A 556 GLY A 566	AGS A 999 ( 4.4A) AGS A 999 (-4.6A) AGS A 999 (-3.6A) None AGS A 999 (-4.5A) None	0.73A	5aaaA-3fzpA: 32.1	5aaaA-3fzpA: 34.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	8	LEU A 226 VAL A 234 ALA A 247 LEU A 301 MET A 304 GLY A 307 LEU A 354 ASP A 368	None	0.97A	5aaaA-3i6uA: 21.8	5aaaA-3i6uA: 23.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 649 ALA A 665 MET A 716 GLY A 719 LEU A 767 ASP A 778	None None None GOL A 403 (-3.4A) None None	0.58A	5aaaA-3kulA: 33.1	5aaaA-3kulA: 32.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	6	LEU A 680 VAL A 689 ALA A 700 LEU A 745 LEU A 804 ASP A 828	ADP A2101 ( 4.1A) ADP A2101 (-4.5A) ADP A2101 (-3.5A) ADP A2101 ( 4.4A) ADP A2101 (-4.4A) SR A2103 (-2.6A)	0.50A	5aaaA-3lj0A: 23.5	5aaaA-3lj0A: 22.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lw0	INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1005 VAL A1013 ALA A1031 MET A1082 GLY A1085 GLY A1152 ASP A1153	None None None None None CCX A 1 (-3.6A) CCX A 1 ( 4.3A)	0.68A	5aaaA-3lw0A: 30.4	5aaaA-3lw0A: 41.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 88 VAL A 96 ALA A 109 GLY A 165 LEU A 212 ASP A 223	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) None None SO4 A 5 ( 4.5A)	0.75A	5aaaA-3nuuA: 24.0	5aaaA-3nuuA: 23.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 88 VAL A 96 ALA A 109 LEU A 159 GLY A 165 ASP A 223	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) JOZ A 361 (-4.0A) None SO4 A 5 ( 4.5A)	0.81A	5aaaA-3nuuA: 24.0	5aaaA-3nuuA: 23.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	8	LEU A 192 VAL A 200 ALA A 213 LEU A 263 MET A 266 GLY A 269 LEU A 318 ASP A 329	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 ( 4.7A) None None AMP A 577 (-4.8A) AMP A 577 (-4.0A)	0.62A	5aaaA-3nyoA: 23.0	5aaaA-3nyoA: 18.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 VAL A 734 ALA A 751 MET A 801 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.48A	5aaaA-3pp0A: 31.6	5aaaA-3pp0A: 34.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 63 VAL A 71 ALA A 84 GLY A 150 LEU A 197 ASP A 211	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.6A) None ANP A1634 (-4.4A) MG A 529 (-2.2A)	0.82A	5aaaA-3q5iA: 21.8	5aaaA-3q5iA: 22.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	LEU A 295 VAL A 303 ALA A 315 MET A 366 GLY A 369 LEU A 423 GLY A 433	None	0.54A	5aaaA-3ulzA: 22.6	5aaaA-3ulzA: 28.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 544 VAL A 552 ALA A 570 MET A 620 GLY A 623 LEU A 686 GLY A 696	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A) 0F4 A 902 (-3.3A)	0.66A	5aaaA-3v5qA: 30.9	5aaaA-3v5qA: 39.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 139 VAL A 147 ALA A 160 LEU A 210 GLY A 216 LEU A 263	N13 A 501 (-3.7A) N13 A 501 ( 4.7A) N13 A 501 ( 4.1A) N13 A 501 ( 4.8A) N13 A 501 (-3.5A) N13 A 501 (-4.5A)	0.76A	5aaaA-3w18A: 21.9	5aaaA-3w18A: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 75 VAL A 83 ALA A 96 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.49A	5aaaA-3wigA: 23.1	5aaaA-3wigA: 24.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 840 VAL A 848 ALA A 866 GLY A 922 LEU A1035 ASP A1046	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.4A)	0.71A	5aaaA-3wzdA: 31.4	5aaaA-3wzdA: 35.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A1951 VAL A1959 ALA A1978 LEU A2026 MET A2029 GLY A2032 LEU A2086 GLY A2101 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A) None	0.34A	5aaaA-3zbfA: 34.5	5aaaA-3zbfA: 47.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 633 ALA A 649 MET A 700 GLY A 703 LEU A 751 ASP A 762	None	0.37A	5aaaA-3zfxA: 34.5	5aaaA-3zfxA: 35.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 VAL A 91 ALA A 104 LEU A 154 GLY A 160 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) None VX6 A 500 (-3.3A) VX6 A 500 (-4.6A)	0.59A	5aaaA-4af3A: 19.3	5aaaA-4af3A: 24.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 560 VAL A 568 ALA A 586 MET A 636 GLY A 639 LEU A 699 GLY A 709 ASP A 710	LTI A1839 ( 4.2A) None LTI A1839 (-3.3A) None LTI A1839 (-3.4A) LTI A1839 (-4.2A) LTI A1839 (-3.4A) None	0.67A	5aaaA-4at3A: 31.2	5aaaA-4at3A: 38.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 105 ALA A 121 MET A 172 GLY A 175 LEU A 223 ASP A 234	30K A1365 ( 4.6A) 30K A1365 (-3.2A) None 30K A1365 (-3.5A) 30K A1365 (-4.5A) 30K A1365 (-3.3A)	0.35A	5aaaA-4aw5A: 34.4	5aaaA-4aw5A: 34.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4b99	MITOGEN-ACTIVATED PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 69 ALA A 82 LEU A 137 MET A 140 LEU A 189 GLY A 199 ASP A 200	R4L A1394 (-4.0A) R4L A1394 ( 3.7A) R4L A1394 (-3.9A) None R4L A1394 (-4.5A) R4L A1394 ( 4.1A) None	0.82A	5aaaA-4b99A: 22.6	5aaaA-4b99A: 23.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 663 VAL A 671 ALA A 684 GLY A 743 LEU A 789 ASP A 800	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) None AGS A1985 (-4.8A) AGS A1985 ( 3.3A)	0.70A	5aaaA-4crsA: 22.0	5aaaA-4crsA: 26.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 515 VAL A 523 ALA A 541 MET A 591 GLY A 594 LEU A 656 GLY A 666 ASP A 667	None	0.59A	5aaaA-4f0iA: 31.2	5aaaA-4f0iA: 39.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 377 VAL A 385 ALA A 400 GLY A 454 LEU A 501 ASP A 512	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 (-3.5A) 0SB A 701 (-4.4A) 0SB A 701 (-3.9A)	0.45A	5aaaA-4f4pA: 31.8	5aaaA-4f4pA: 32.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4feq	TYROSINE-PROTEIN KINASE RECEPTOR TYRO3 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 514 VAL A 522 ALA A 538 LEU A 593 MET A 596 GLY A 599 ASP A 663	0T8 A 901 (-3.6A) 0T8 A 901 ( 4.4A) 0T8 A 901 (-3.2A) 0T8 A 901 (-3.7A) None 0T8 A 901 ( 3.8A) 0T8 A 901 (-4.5A)	0.90A	5aaaA-4feqA: 20.2	5aaaA-4feqA: 37.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A1122 VAL A1130 ALA A1148 LEU A1196 MET A1199 GLY A1202 LEU A1256 GLY A1269 ASP A1270	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 (-3.7A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A) 0UV A1501 (-4.5A) 0UV A1501 ( 4.2A)	0.44A	5aaaA-4fodA: 46.6	5aaaA-4fodA: 94.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 ALA A 880 GLY A 935 LEU A 983 GLY A 993 ASP A 994	IZA A2001 (-3.7A) IZA A2001 (-3.4A) IZA A2001 (-3.3A) IZA A2001 ( 4.7A) None IZA A2001 ( 4.5A)	0.60A	5aaaA-4gl9A: 29.3	5aaaA-4gl9A: 30.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 VAL A 863 ALA A 880 GLY A 935 LEU A 983 GLY A 993	IZA A2001 (-3.7A) None IZA A2001 (-3.4A) IZA A2001 (-3.3A) IZA A2001 ( 4.7A) None	0.63A	5aaaA-4gl9A: 29.3	5aaaA-4gl9A: 30.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 828 VAL A 836 ALA A 853 GLY A 908 LEU A 956 ASP A 967	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.79A	5aaaA-4hviA: 23.4	5aaaA-4hviA: 29.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 VAL A 140 ALA A 156 GLY A 211 LEU A 259 GLY A 269	None	0.38A	5aaaA-4hzsA: 28.7	5aaaA-4hzsA: 33.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 132 VAL A 140 ALA A 156 GLY A 211 LEU A 259 GLY A 269 ASP A 270	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A) None None	0.61A	5aaaA-4id7A: 31.5	5aaaA-4id7A: 33.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jrn	RHOPTRY KINASE FAMILY PROTEIN (Toxoplasma gondii)	PF14531 (Kinase-like)	6	LEU A 258 VAL A 266 ALA A 279 LEU A 416 GLY A 426 ASP A 427	ANP A 601 ( 4.6A) ANP A 601 (-4.1A) ANP A 601 ( 3.9A) ANP A 601 ( 4.9A) None MG A 603 ( 2.0A)	0.68A	5aaaA-4jrnA: 20.2	5aaaA-4jrnA: 23.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 18 VAL A 26 ALA A 39 LEU A 89 GLY A 95 LEU A 143 ASP A 154	631 A 301 (-3.4A) 631 A 301 (-4.6A) 631 A 301 (-3.3A) 631 A 301 ( 4.5A) 631 A 301 ( 3.7A) 631 A 301 (-4.0A) EDO A 302 (-3.7A)	0.83A	5aaaA-4jxfA: 19.0	5aaaA-4jxfA: 24.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A)	0.51A	5aaaA-4k11A: 30.2	5aaaA-4k11A: 26.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 478 VAL A 486 ALA A 506 GLY A 561 LEU A 624 ASP A 635	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.6A) ACP A 801 (-4.4A) MG A 802 ( 3.0A)	0.67A	5aaaA-4k33A: 32.6	5aaaA-4k33A: 38.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.39A	5aaaA-4lggA: 29.9	5aaaA-4lggA: 33.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 46 VAL A 54 ALA A 67 GLY A 128 LEU A 180 ASP A 191	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.68A	5aaaA-4o38A: 20.8	5aaaA-4o38A: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 ALA A 928 GLY A 984 LEU A1030 GLY A1040 ASP A1041	2TT A1202 (-3.5A) 2TT A1202 ( 3.9A) 2TT A1202 (-3.4A) 2TT A1202 (-4.4A) 2TT A1202 (-3.4A) 2TT A1202 (-4.6A)	0.71A	5aaaA-4oliA: 27.4	5aaaA-4oliA: 23.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 627 ALA A 644 MET A 695 GLY A 698 LEU A 746 ASP A 757	None	0.66A	5aaaA-4p2kA: 35.0	5aaaA-4p2kA: 36.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 192 VAL A 200 ALA A 213 LEU A 263 MET A 266 LEU A 318	SGV A 601 (-4.1A) SGV A 601 ( 4.6A) SGV A 601 (-3.3A) SGV A 601 (-4.5A) None SGV A 601 (-4.9A)	0.75A	5aaaA-4tnbA: 16.3	5aaaA-4tnbA: 19.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	LEU A 14 VAL A 22 ALA A 35 MET A 84 GLY A 87 LEU A 136 ASP A 147	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-3.5A) ACP A1264 ( 4.8A) None	0.43A	5aaaA-4ueuA: 32.5	5aaaA-4ueuA: 40.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uya	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 138 ALA A 149 LEU A 200 GLY A 206 LEU A 270 ASP A 289	AGS A1438 (-4.4A) AGS A1438 (-3.4A) AGS A1438 (-3.6A) None AGS A1438 (-4.7A) AGS A1438 (-2.7A)	0.73A	5aaaA-4uyaA: 27.1	5aaaA-4uyaA: 32.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 VAL A 201 ALA A 214 MET A 267 GLY A 270 LEU A 321 ASP A 332	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) None ANW A 601 ( 4.5A) ANW A 601 (-4.9A) None	0.58A	5aaaA-4wboA: 23.6	5aaaA-4wboA: 23.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 52 VAL A 60 ALA A 72 GLY A 132 LEU A 183 ASP A 194	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) ZN A 403 ( 2.6A)	0.77A	5aaaA-4wsqA: 23.9	5aaaA-4wsqA: 24.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.36A	5aaaA-4xeyB: 31.0	5aaaA-4xeyB: 32.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.75A	5aaaA-4xi2A: 31.8	5aaaA-4xi2A: 27.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) None 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.36A	5aaaA-4y93A: 31.9	5aaaA-4y93A: 26.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 VAL A 201 ALA A 214 LEU A 264 MET A 267 LEU A 319 ASP A 330	AN2 A 601 ( 4.2A) AN2 A 601 (-4.0A) AN2 A 601 (-3.6A) AN2 A 601 ( 4.8A) None None AN2 A 601 (-3.0A)	0.67A	5aaaA-4yhjA: 21.7	5aaaA-4yhjA: 20.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 VAL A 201 MET A 267 GLY A 270 LEU A 319 ASP A 330	AN2 A 601 ( 4.2A) AN2 A 601 (-4.0A) None None None AN2 A 601 (-3.0A)	0.85A	5aaaA-4yhjA: 21.7	5aaaA-4yhjA: 20.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	7	LEU A 99 VAL A 107 ALA A 120 LEU A 170 GLY A 176 LEU A 223 ASP A 234	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-3.8A) 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A) None	0.98A	5aaaA-5eykA: 24.8	5aaaA-5eykA: 27.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 GLY A 984 LEU A1030 GLY A1040	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A) 5U3 A1200 ( 4.9A)	0.69A	5aaaA-5f1zA: 28.1	5aaaA-5f1zA: 31.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hor	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1092 ALA A1108 LEU A1157 MET A1160 GLY A1163 ASP A1222	63K A1401 (-4.9A) 63K A1401 (-3.5A) 63K A1401 (-4.2A) None 63K A1401 (-3.6A) None	0.63A	5aaaA-5horA: 24.8	5aaaA-5horA: 33.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	6	LEU A 20 VAL A 28 ALA A 41 GLY A 96 LEU A 143 ASP A 157	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) None ADP A 301 (-4.7A) MG A 302 ( 3.3A)	0.81A	5aaaA-5hu3A: 25.1	5aaaA-5hu3A: 25.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 718 VAL A 726 ALA A 743 MET A 793 GLY A 796 ASP A 855	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.5A) 6HJ A1101 (-4.3A)	0.71A	5aaaA-5j9zA: 32.8	5aaaA-5j9zA: 31.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 718 VAL A 726 ALA A 743 MET A 793 GLY A 796 LEU A 844	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A)	0.37A	5aaaA-5j9zA: 32.8	5aaaA-5j9zA: 31.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 404 ALA A 417 GLY A 471 LEU A 518 GLY A 532 ASP A 533	GUI A 701 (-4.4A) GUI A 701 ( 3.9A) GUI A 701 (-3.6A) GUI A 701 (-4.4A) GUI A 701 ( 4.7A) GUI A 701 ( 4.8A)	0.66A	5aaaA-5jznA: 23.2	5aaaA-5jznA: 25.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 897 ALA A 909 MET A 959 GLY A 962 LEU A1016 ASP A1027	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) None ATP A1200 ( 4.0A) ATP A1200 (-4.6A) ATP A1200 (-4.1A)	0.48A	5aaaA-5lpyA: 23.4	5aaaA-5lpyA: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 897 ALA A 909 MET A 959 GLY A 962 LEU A1016 ASP A1027	ADP A1200 (-4.4A) ADP A1200 (-3.5A) None ADP A1200 ( 4.0A) ADP A1200 (-4.7A) ADP A1200 (-3.4A)	0.39A	5aaaA-5lpzA: 23.4	5aaaA-5lpzA: 26.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 593 VAL A 601 ALA A 617 LEU A 671 MET A 674 GLY A 677 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.50A	5aaaA-5td2A: 12.8	5aaaA-5td2A: 38.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tur	SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	no annotation	6	LEU A 44 VAL A 52 ALA A 65 LEU A 120 LEU A 174 ASP A 186	None 7LK A 401 (-4.9A) 7LK A 401 (-3.3A) 7LK A 401 (-4.0A) 7LK A 401 (-4.8A) None	0.85A	5aaaA-5turA: 21.8	5aaaA-5turA: 22.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 542 VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.51A	5aaaA-5u6bA: 30.6	5aaaA-5u6bA: 40.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 106 ALA A 119 MET A 172 GLY A 175 LEU A 221 ASP A 232	None	0.64A	5aaaA-5u7qA: 20.9	5aaaA-5u7qA: 23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	VAL A 205 ALA A 218 LEU A 271 MET A 274 LEU A 324 ASP A 335	QRW A 601 (-4.7A) QRW A 601 (-3.4A) QRW A 601 ( 4.9A) MES A 604 (-3.9A) None QRW A 601 (-3.7A)	0.84A	5aaaA-5uuuA: 22.6	5aaaA-5uuuA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	LEU A 24 VAL A 32 ALA A 45 MET A 98 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.62A	5aaaA-5w5jA: 9.5	5aaaA-5w5jA: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wnm	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 4 (Mus musculus)	no annotation	6	VAL A 36 ALA A 49 MET A 99 GLY A 102 LEU A 150 ASP A 161	VX6 A 402 (-4.6A) VX6 A 402 (-3.2A) None VX6 A 402 (-3.5A) VX6 A 402 (-4.4A) VX6 A 402 (-4.3A)	0.50A	5aaaA-5wnmA: 28.2	5aaaA-5wnmA: 15.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 ALA A 906 GLY A 962 LEU A1010 GLY A1020 ASP A1021	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) ADP A1201 ( 4.1A) ADP A1201 (-4.5A) None MG A1203 (-1.8A)	0.63A	5aaaA-6c7yA: 29.1	5aaaA-6c7yA: 15.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	7	LEU A 197 VAL A 205 ALA A 217 MET A 267 GLY A 270 LEU A 319 GLY A 329	FKY A9001 (-4.1A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) None FKY A9001 (-3.3A) FKY A9001 ( 4.9A) FKY A9001 (-3.4A)	0.89A	5aaaA-6cz4A: 30.0	5aaaA-6cz4A: 19.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	6	VAL A 200 ALA A 211 MET A 265 GLY A 268 LEU A 318 ASP A 329	CJT A 502 ( 4.8A) CJT A 502 (-3.4A) CJT A 502 (-4.9A) CJT A 502 ( 4.3A) CJT A 502 (-4.7A) CJT A 502 ( 4.0A)	0.53A	5aaaA-6f3dA: 24.5	5aaaA-6f3dA: 13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	6	LEU U 20 VAL U 28 ALA U 42 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.68A	5aaaA-6fdyU: 22.2	5aaaA-6fdyU: undetectable

[["5AAA_A_VGHA9000_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.65A","5aaaA-1k9aA:32.9","5aaaA-1k9aA:25.83"],["5AAA_A_VGHA9000_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"VAL A 588;ALA A 606;MET A 657;GLY A 660;LEU A 731;ASP A 742","None","0.67A","5aaaA-1lufA:33.1","5aaaA-1lufA:35.46"],["5AAA_A_VGHA9000_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.56A","5aaaA-1opkA:31.0","5aaaA-1opkA:26.17"],["5AAA_A_VGHA9000_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"LEU A  78;VAL A  86;ALA A  99;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.49A","5aaaA-1s9iA:22.1","5aaaA-1s9iA:25.06"],["5AAA_A_VGHA9000_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"LEU A 344;VAL A 352;ALA A 367;GLY A 420;LEU A 468;ASP A 479","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);STU A 100 (-3.5A);STU A 100 (-4.5A);STU A 100 (-3.5A)","0.78A","5aaaA-1u59A:32.3","5aaaA-1u59A:33.43"],["5AAA_A_VGHA9000_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;GLY A 110;LEU A 158;GLY A 168;ASP A 169","None","0.72A","5aaaA-1u5qA:25.5","5aaaA-1u5qA:29.73"],["5AAA_A_VGHA9000_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LEU A  84;GLY A  90;LEU A 137;ASP A 148","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-4.2A);None;HYM A 400 (-4.5A);HYM A 400 (-3.9A)","0.85A","5aaaA-1zltA:21.3","5aaaA-1zltA:24.48"],["5AAA_A_VGHA9000_1","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",7,"LEU A  26;VAL A  34;ALA A  47;LEU A  98;GLY A 104;LEU A 155;ASP A 166","STU A1301 (-4.2A);STU A1301 (-4.8A);STU A1301 (-3.6A);STU A1301 ( 4.7A);STU A1301 ( 4.0A);STU A1301 ( 4.8A);None","0.69A","5aaaA-2bujA:23.9","5aaaA-2bujA:25.14"],["5AAA_A_VGHA9000_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;MET X  85;GLY X  88;LEU X 137;ASP X 148","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 (-3.6A)","0.70A","5aaaA-2dq7X:31.9","5aaaA-2dq7X:37.50"],["5AAA_A_VGHA9000_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;ALA A  40;MET A  96;LEU A 144;ASP A 155","ADP A 500 (-4.3A);ADP A 500 (-4.3A);ADP A 500 ( 3.7A);None;ADP A 500 (-4.3A);ADP A 500 ( 2.9A)","0.76A","5aaaA-2f9gA:22.6","5aaaA-2f9gA:23.47"],["5AAA_A_VGHA9000_1","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;GLY A 110;LEU A 158;GLY A 168;ASP A 169","STU A 400 ( 4.8A);STU A 400 (-3.2A);STU A 400 (-3.4A);STU A 400 ( 4.6A);None;STU A 400 (-3.6A)","0.66A","5aaaA-2gcdA:26.4","5aaaA-2gcdA:28.37"],["5AAA_A_VGHA9000_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ASP A 404","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 (-4.2A)","0.63A","5aaaA-2h8hA:30.4","5aaaA-2h8hA:22.97"],["5AAA_A_VGHA9000_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.58A","5aaaA-2hckA:29.5","5aaaA-2hckA:26.50"],["5AAA_A_VGHA9000_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;ALA A 271;MET A 319;GLY A 322;LEU A 371;ASP A 382","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);None;1BM A 499 (-3.5A);1BM A 499 (-4.4A);1BM A 499 (-4.4A)","0.52A","5aaaA-2hk5A:24.1","5aaaA-2hk5A:37.30"],["5AAA_A_VGHA9000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"LEU A 248;VAL A 256;ALA A 269;MET A 318;GLY A 321;LEU A 370;ASP A 381","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);None;None;GIN A 600 (-4.7A);GIN A 600 (-4.9A)","0.80A","5aaaA-2hz0A:31.1","5aaaA-2hz0A:37.31"],["5AAA_A_VGHA9000_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",6,"VAL A 436;ALA A 452;GLY A 505;LEU A 553;GLY A 563;ASP A 564","4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 (-3.2A);4ST A1687 (-4.4A);None;4ST A1687 (-4.7A)","0.69A","5aaaA-2j0jA:33.1","5aaaA-2j0jA:19.85"],["5AAA_A_VGHA9000_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",6,"LEU A 251;VAL A 259;ALA A 271;MET A 319;GLY A 322;LEU A 371","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.69A","5aaaA-2og8A:30.4","5aaaA-2og8A:40.14"],["5AAA_A_VGHA9000_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;VAL A 596;ALA A 614;GLY A 669;LEU A 785;GLY A 795;ASP A 796","None","0.79A","5aaaA-2ogvA:30.9","5aaaA-2ogvA:36.36"],["5AAA_A_VGHA9000_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"LEU A  25;VAL A  33;ALA A  46;MET A 106;GLY A 109;LEU A 156;ASP A 167","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;ATP A 381 ( 4.8A); MN A 382 (-2.0A)","0.66A","5aaaA-2phkA:23.0","5aaaA-2phkA:23.08"],["5AAA_A_VGHA9000_1","2pmi","Saccharomyces cerevisiae","CYCLIN-DEPENDENT PROTEIN KINASE PHO85","PF00069(Pkinase)",6,"VAL A  21;ALA A  34;MET A  85;LEU A 140;GLY A 150;ASP A 151","AGS A3001 (-4.4A);AGS A3001 (-3.5A);None;None;None;AGS A3001 (-2.8A)","0.70A","5aaaA-2pmiA:15.1","5aaaA-2pmiA:25.48"],["5AAA_A_VGHA9000_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL B  55;ALA B  67;MET B 117;GLY B 120;LEU B 171;ASP B 182","None","0.51A","5aaaA-2qkwB:24.6","5aaaA-2qkwB:27.58"],["5AAA_A_VGHA9000_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;MET A 702;GLY A 705;LEU A 753;ASP A 764","BME A   1 (-4.9A);PTR A 701 ( 4.7A);PTR A 701 ( 3.5A);None;None;None","0.49A","5aaaA-2qobA:34.5","5aaaA-2qobA:33.60"],["5AAA_A_VGHA9000_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 689;ALA A 705;MET A 756;GLY A 759;LEU A 807;ASP A 818","None","0.33A","5aaaA-2r2pA:34.6","5aaaA-2r2pA:33.63"],["5AAA_A_VGHA9000_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;VAL A 732;ALA A 749;MET A 799;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.49A","5aaaA-2r4bA:30.5","5aaaA-2r4bA:32.35"],["5AAA_A_VGHA9000_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"LEU A 226;VAL A 234;ALA A 247;LEU A 301;MET A 304;GLY A 307;LEU A 354","XK9 A1511 (-3.8A);XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.6A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A)","0.76A","5aaaA-2xk9A:21.6","5aaaA-2xk9A:25.63"],["5AAA_A_VGHA9000_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"VAL A 234;ALA A 247;LEU A 301;MET A 304;GLY A 307;LEU A 354;ASP A 368","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.6A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A);XK9 A1511 (-3.6A)","0.84A","5aaaA-2xk9A:21.6","5aaaA-2xk9A:25.63"],["5AAA_A_VGHA9000_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;MET A 702;GLY A 705;LEU A 753;ASP A 764","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A);None","0.67A","5aaaA-2xyuA:26.4","5aaaA-2xyuA:34.80"],["5AAA_A_VGHA9000_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"LEU A  68;VAL A  76;ALA A  92;LEU A 141;GLY A 147;LEU A 194;ASP A 205","STU A   1 (-3.8A);None;STU A   1 (-3.3A);STU A   1 ( 4.6A);STU A   1 ( 3.9A);STU A   1 (-4.6A);STU A   1 ( 3.8A)","0.83A","5aaaA-2z7rA:21.8","5aaaA-2z7rA:24.23"],["5AAA_A_VGHA9000_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1002;VAL A1010;ALA A1028;MET A1079;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None;None","0.47A","5aaaA-2z8cA:30.5","5aaaA-2z8cA:44.10"],["5AAA_A_VGHA9000_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"LEU A 253;VAL A 261;ALA A 273;MET A 322;GLY A 325;LEU A 374;ASP A 385","None","0.54A","5aaaA-2zv7A:32.8","5aaaA-2zv7A:35.76"],["5AAA_A_VGHA9000_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.65A","5aaaA-3d7uA:26.3","5aaaA-3d7uA:34.15"],["5AAA_A_VGHA9000_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",6,"LEU A 431;VAL A 439;ALA A 455;GLY A 508;LEU A 556;GLY A 566","AGS A 999 ( 4.4A);AGS A 999 (-4.6A);AGS A 999 (-3.6A);None;AGS A 999 (-4.5A);None","0.73A","5aaaA-3fzpA:32.1","5aaaA-3fzpA:34.82"],["5AAA_A_VGHA9000_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",8,"LEU A 226;VAL A 234;ALA A 247;LEU A 301;MET A 304;GLY A 307;LEU A 354;ASP A 368","None","0.97A","5aaaA-3i6uA:21.8","5aaaA-3i6uA:23.22"],["5AAA_A_VGHA9000_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 649;ALA A 665;MET A 716;GLY A 719;LEU A 767;ASP A 778","None;None;None;GOL A 403 (-3.4A);None;None","0.58A","5aaaA-3kulA:33.1","5aaaA-3kulA:32.01"],["5AAA_A_VGHA9000_1","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",6,"LEU A 680;VAL A 689;ALA A 700;LEU A 745;LEU A 804;ASP A 828","ADP A2101 ( 4.1A);ADP A2101 (-4.5A);ADP A2101 (-3.5A);ADP A2101 ( 4.4A);ADP A2101 (-4.4A); SR A2103 (-2.6A)","0.50A","5aaaA-3lj0A:23.5","5aaaA-3lj0A:22.50"],["5AAA_A_VGHA9000_1","3lw0","Homo sapiens","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1005;VAL A1013;ALA A1031;MET A1082;GLY A1085;GLY A1152;ASP A1153","None;None;None;None;None;CCX A   1 (-3.6A);CCX A   1 ( 4.3A)","0.68A","5aaaA-3lw0A:30.4","5aaaA-3lw0A:41.06"],["5AAA_A_VGHA9000_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"LEU A  88;VAL A  96;ALA A 109;GLY A 165;LEU A 212;ASP A 223","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);None;None;SO4 A   5 ( 4.5A)","0.75A","5aaaA-3nuuA:24.0","5aaaA-3nuuA:23.50"],["5AAA_A_VGHA9000_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"LEU A  88;VAL A  96;ALA A 109;LEU A 159;GLY A 165;ASP A 223","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);JOZ A 361 (-4.0A);None;SO4 A   5 ( 4.5A)","0.81A","5aaaA-3nuuA:24.0","5aaaA-3nuuA:23.50"],["5AAA_A_VGHA9000_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",8,"LEU A 192;VAL A 200;ALA A 213;LEU A 263;MET A 266;GLY A 269;LEU A 318;ASP A 329","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 ( 4.7A);None;None;AMP A 577 (-4.8A);AMP A 577 (-4.0A)","0.62A","5aaaA-3nyoA:23.0","5aaaA-3nyoA:18.85"],["5AAA_A_VGHA9000_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;VAL A 734;ALA A 751;MET A 801;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.48A","5aaaA-3pp0A:31.6","5aaaA-3pp0A:34.09"],["5AAA_A_VGHA9000_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  63;VAL A  71;ALA A  84;GLY A 150;LEU A 197;ASP A 211","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.6A);None;ANP A1634 (-4.4A); MG A 529 (-2.2A)","0.82A","5aaaA-3q5iA:21.8","5aaaA-3q5iA:22.46"],["5AAA_A_VGHA9000_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",7,"LEU A 295;VAL A 303;ALA A 315;MET A 366;GLY A 369;LEU A 423;GLY A 433","None","0.54A","5aaaA-3ulzA:22.6","5aaaA-3ulzA:28.21"],["5AAA_A_VGHA9000_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 544;VAL A 552;ALA A 570;MET A 620;GLY A 623;LEU A 686;GLY A 696","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A);0F4 A 902 (-3.3A)","0.66A","5aaaA-3v5qA:30.9","5aaaA-3v5qA:39.33"],["5AAA_A_VGHA9000_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",6,"LEU A 139;VAL A 147;ALA A 160;LEU A 210;GLY A 216;LEU A 263","N13 A 501 (-3.7A);N13 A 501 ( 4.7A);N13 A 501 ( 4.1A);N13 A 501 ( 4.8A);N13 A 501 (-3.5A);N13 A 501 (-4.5A)","0.76A","5aaaA-3w18A:21.9","5aaaA-3w18A:25.07"],["5AAA_A_VGHA9000_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"LEU A  75;VAL A  83;ALA A  96;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.49A","5aaaA-3wigA:23.1","5aaaA-3wigA:24.44"],["5AAA_A_VGHA9000_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 840;VAL A 848;ALA A 866;GLY A 922;LEU A1035;ASP A1046","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.4A)","0.71A","5aaaA-3wzdA:31.4","5aaaA-3wzdA:35.95"],["5AAA_A_VGHA9000_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",9,"LEU A1951;VAL A1959;ALA A1978;LEU A2026;MET A2029;GLY A2032;LEU A2086;GLY A2101;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A);None","0.34A","5aaaA-3zbfA:34.5","5aaaA-3zbfA:47.90"],["5AAA_A_VGHA9000_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 633;ALA A 649;MET A 700;GLY A 703;LEU A 751;ASP A 762","None","0.37A","5aaaA-3zfxA:34.5","5aaaA-3zfxA:35.33"],["5AAA_A_VGHA9000_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;VAL A  91;ALA A 104;LEU A 154;GLY A 160;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);None;VX6 A 500 (-3.3A);VX6 A 500 (-4.6A)","0.59A","5aaaA-4af3A:19.3","5aaaA-4af3A:24.01"],["5AAA_A_VGHA9000_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 560;VAL A 568;ALA A 586;MET A 636;GLY A 639;LEU A 699;GLY A 709;ASP A 710","LTI A1839 ( 4.2A);None;LTI A1839 (-3.3A);None;LTI A1839 (-3.4A);LTI A1839 (-4.2A);LTI A1839 (-3.4A);None","0.67A","5aaaA-4at3A:31.2","5aaaA-4at3A:38.14"],["5AAA_A_VGHA9000_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"VAL A 105;ALA A 121;MET A 172;GLY A 175;LEU A 223;ASP A 234","30K A1365 ( 4.6A);30K A1365 (-3.2A);None;30K A1365 (-3.5A);30K A1365 (-4.5A);30K A1365 (-3.3A)","0.35A","5aaaA-4aw5A:34.4","5aaaA-4aw5A:34.24"],["5AAA_A_VGHA9000_1","4b99","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 7","PF00069(Pkinase)",7,"VAL A  69;ALA A  82;LEU A 137;MET A 140;LEU A 189;GLY A 199;ASP A 200","R4L A1394 (-4.0A);R4L A1394 ( 3.7A);R4L A1394 (-3.9A);None;R4L A1394 (-4.5A);R4L A1394 ( 4.1A);None","0.82A","5aaaA-4b99A:22.6","5aaaA-4b99A:23.60"],["5AAA_A_VGHA9000_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 663;VAL A 671;ALA A 684;GLY A 743;LEU A 789;ASP A 800","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;AGS A1985 (-4.8A);AGS A1985 ( 3.3A)","0.70A","5aaaA-4crsA:22.0","5aaaA-4crsA:26.67"],["5AAA_A_VGHA9000_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 515;VAL A 523;ALA A 541;MET A 591;GLY A 594;LEU A 656;GLY A 666;ASP A 667","None","0.59A","5aaaA-4f0iA:31.2","5aaaA-4f0iA:39.26"],["5AAA_A_VGHA9000_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"LEU A 377;VAL A 385;ALA A 400;GLY A 454;LEU A 501;ASP A 512","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 (-3.5A);0SB A 701 (-4.4A);0SB A 701 (-3.9A)","0.45A","5aaaA-4f4pA:31.8","5aaaA-4f4pA:32.93"],["5AAA_A_VGHA9000_1","4feq","Mus musculus","TYROSINE-PROTEIN KINASE RECEPTOR TYRO3","PF07714(Pkinase_Tyr)",7,"LEU A 514;VAL A 522;ALA A 538;LEU A 593;MET A 596;GLY A 599;ASP A 663","0T8 A 901 (-3.6A);0T8 A 901 ( 4.4A);0T8 A 901 (-3.2A);0T8 A 901 (-3.7A);None;0T8 A 901 ( 3.8A);0T8 A 901 (-4.5A)","0.90A","5aaaA-4feqA:20.2","5aaaA-4feqA:37.18"],["5AAA_A_VGHA9000_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",9,"LEU A1122;VAL A1130;ALA A1148;LEU A1196;MET A1199;GLY A1202;LEU A1256;GLY A1269;ASP A1270","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 (-3.7A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A);0UV A1501 (-4.5A);0UV A1501 ( 4.2A)","0.44A","5aaaA-4fodA:46.6","5aaaA-4fodA:94.89"],["5AAA_A_VGHA9000_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;ALA A 880;GLY A 935;LEU A 983;GLY A 993;ASP A 994","IZA A2001 (-3.7A);IZA A2001 (-3.4A);IZA A2001 (-3.3A);IZA A2001 ( 4.7A);None;IZA A2001 ( 4.5A)","0.60A","5aaaA-4gl9A:29.3","5aaaA-4gl9A:30.15"],["5AAA_A_VGHA9000_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;VAL A 863;ALA A 880;GLY A 935;LEU A 983;GLY A 993","IZA A2001 (-3.7A);None;IZA A2001 (-3.4A);IZA A2001 (-3.3A);IZA A2001 ( 4.7A);None","0.63A","5aaaA-4gl9A:29.3","5aaaA-4gl9A:30.15"],["5AAA_A_VGHA9000_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"LEU A 828;VAL A 836;ALA A 853;GLY A 908;LEU A 956;ASP A 967","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.79A","5aaaA-4hviA:23.4","5aaaA-4hviA:29.55"],["5AAA_A_VGHA9000_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;VAL A 140;ALA A 156;GLY A 211;LEU A 259;GLY A 269","None","0.38A","5aaaA-4hzsA:28.7","5aaaA-4hzsA:33.61"],["5AAA_A_VGHA9000_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 132;VAL A 140;ALA A 156;GLY A 211;LEU A 259;GLY A 269;ASP A 270","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A);None;None","0.61A","5aaaA-4id7A:31.5","5aaaA-4id7A:33.63"],["5AAA_A_VGHA9000_1","4jrn","Toxoplasma gondii","RHOPTRY KINASE FAMILY PROTEIN","PF14531(Kinase-like)",6,"LEU A 258;VAL A 266;ALA A 279;LEU A 416;GLY A 426;ASP A 427","ANP A 601 ( 4.6A);ANP A 601 (-4.1A);ANP A 601 ( 3.9A);ANP A 601 ( 4.9A);None; MG A 603 ( 2.0A)","0.68A","5aaaA-4jrnA:20.2","5aaaA-4jrnA:23.47"],["5AAA_A_VGHA9000_1","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",7,"LEU A  18;VAL A  26;ALA A  39;LEU A  89;GLY A  95;LEU A 143;ASP A 154","631 A 301 (-3.4A);631 A 301 (-4.6A);631 A 301 (-3.3A);631 A 301 ( 4.5A);631 A 301 ( 3.7A);631 A 301 (-4.0A);EDO A 302 (-3.7A)","0.83A","5aaaA-4jxfA:19.0","5aaaA-4jxfA:24.76"],["5AAA_A_VGHA9000_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A)","0.51A","5aaaA-4k11A:30.2","5aaaA-4k11A:26.05"],["5AAA_A_VGHA9000_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"LEU A 478;VAL A 486;ALA A 506;GLY A 561;LEU A 624;ASP A 635","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.6A);ACP A 801 (-4.4A); MG A 802 ( 3.0A)","0.67A","5aaaA-4k33A:32.6","5aaaA-4k33A:38.30"],["5AAA_A_VGHA9000_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.39A","5aaaA-4lggA:29.9","5aaaA-4lggA:33.84"],["5AAA_A_VGHA9000_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",6,"LEU A  46;VAL A  54;ALA A  67;GLY A 128;LEU A 180;ASP A 191","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.68A","5aaaA-4o38A:20.8","5aaaA-4o38A:24.79"],["5AAA_A_VGHA9000_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;ALA A 928;GLY A 984;LEU A1030;GLY A1040;ASP A1041","2TT A1202 (-3.5A);2TT A1202 ( 3.9A);2TT A1202 (-3.4A);2TT A1202 (-4.4A);2TT A1202 (-3.4A);2TT A1202 (-4.6A)","0.71A","5aaaA-4oliA:27.4","5aaaA-4oliA:23.08"],["5AAA_A_VGHA9000_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 627;ALA A 644;MET A 695;GLY A 698;LEU A 746;ASP A 757","None","0.66A","5aaaA-4p2kA:35.0","5aaaA-4p2kA:36.75"],["5AAA_A_VGHA9000_1","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 192;VAL A 200;ALA A 213;LEU A 263;MET A 266;LEU A 318","SGV A 601 (-4.1A);SGV A 601 ( 4.6A);SGV A 601 (-3.3A);SGV A 601 (-4.5A);None;SGV A 601 (-4.9A)","0.75A","5aaaA-4tnbA:16.3","5aaaA-4tnbA:19.87"],["5AAA_A_VGHA9000_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"LEU A  14;VAL A  22;ALA A  35;MET A  84;GLY A  87;LEU A 136;ASP A 147","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A);None","0.43A","5aaaA-4ueuA:32.5","5aaaA-4ueuA:40.99"],["5AAA_A_VGHA9000_1","4uya","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4","PF07714(Pkinase_Tyr)",6,"VAL A 138;ALA A 149;LEU A 200;GLY A 206;LEU A 270;ASP A 289","AGS A1438 (-4.4A);AGS A1438 (-3.4A);AGS A1438 (-3.6A);None;AGS A1438 (-4.7A);AGS A1438 (-2.7A)","0.73A","5aaaA-4uyaA:27.1","5aaaA-4uyaA:32.24"],["5AAA_A_VGHA9000_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;VAL A 201;ALA A 214;MET A 267;GLY A 270;LEU A 321;ASP A 332","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A);None","0.58A","5aaaA-4wboA:23.6","5aaaA-4wboA:23.32"],["5AAA_A_VGHA9000_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  52;VAL A  60;ALA A  72;GLY A 132;LEU A 183;ASP A 194","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);KSA A 405 (-3.5A);KSA A 405 (-4.6A); ZN A 403 ( 2.6A)","0.77A","5aaaA-4wsqA:23.9","5aaaA-4wsqA:24.71"],["5AAA_A_VGHA9000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.36A","5aaaA-4xeyB:31.0","5aaaA-4xeyB:32.15"],["5AAA_A_VGHA9000_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.75A","5aaaA-4xi2A:31.8","5aaaA-4xi2A:27.16"],["5AAA_A_VGHA9000_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);None;746 A 702 (-3.6A);746 A 702 (-4.4A)","0.36A","5aaaA-4y93A:31.9","5aaaA-4y93A:26.95"],["5AAA_A_VGHA9000_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;VAL A 201;ALA A 214;LEU A 264;MET A 267;LEU A 319;ASP A 330","AN2 A 601 ( 4.2A);AN2 A 601 (-4.0A);AN2 A 601 (-3.6A);AN2 A 601 ( 4.8A);None;None;AN2 A 601 (-3.0A)","0.67A","5aaaA-4yhjA:21.7","5aaaA-4yhjA:20.17"],["5AAA_A_VGHA9000_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;VAL A 201;MET A 267;GLY A 270;LEU A 319;ASP A 330","AN2 A 601 ( 4.2A);AN2 A 601 (-4.0A);None;None;None;AN2 A 601 (-3.0A)","0.85A","5aaaA-4yhjA:21.7","5aaaA-4yhjA:20.17"],["5AAA_A_VGHA9000_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",7,"LEU A  99;VAL A 107;ALA A 120;LEU A 170;GLY A 176;LEU A 223;ASP A 234","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-3.8A);5U5 A 401 (-3.4A);5U5 A 401 (-4.7A);None","0.98A","5aaaA-5eykA:24.8","5aaaA-5eykA:27.69"],["5AAA_A_VGHA9000_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;GLY A 984;LEU A1030;GLY A1040","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A);5U3 A1200 ( 4.9A)","0.69A","5aaaA-5f1zA:28.1","5aaaA-5f1zA:31.59"],["5AAA_A_VGHA9000_1","5hor","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1092;ALA A1108;LEU A1157;MET A1160;GLY A1163;ASP A1222","63K A1401 (-4.9A);63K A1401 (-3.5A);63K A1401 (-4.2A);None;63K A1401 (-3.6A);None","0.63A","5aaaA-5horA:24.8","5aaaA-5horA:33.04"],["5AAA_A_VGHA9000_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",6,"LEU A  20;VAL A  28;ALA A  41;GLY A  96;LEU A 143;ASP A 157","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;ADP A 301 (-4.7A); MG A 302 ( 3.3A)","0.81A","5aaaA-5hu3A:25.1","5aaaA-5hu3A:25.89"],["5AAA_A_VGHA9000_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 718;VAL A 726;ALA A 743;MET A 793;GLY A 796;ASP A 855","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.5A);6HJ A1101 (-4.3A)","0.71A","5aaaA-5j9zA:32.8","5aaaA-5j9zA:31.71"],["5AAA_A_VGHA9000_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 718;VAL A 726;ALA A 743;MET A 793;GLY A 796;LEU A 844","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A)","0.37A","5aaaA-5j9zA:32.8","5aaaA-5j9zA:31.71"],["5AAA_A_VGHA9000_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",6,"VAL A 404;ALA A 417;GLY A 471;LEU A 518;GLY A 532;ASP A 533","GUI A 701 (-4.4A);GUI A 701 ( 3.9A);GUI A 701 (-3.6A);GUI A 701 (-4.4A);GUI A 701 ( 4.7A);GUI A 701 ( 4.8A)","0.66A","5aaaA-5jznA:23.2","5aaaA-5jznA:25.80"],["5AAA_A_VGHA9000_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"VAL A 897;ALA A 909;MET A 959;GLY A 962;LEU A1016;ASP A1027","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A);ATP A1200 (-4.1A)","0.48A","5aaaA-5lpyA:23.4","5aaaA-5lpyA:26.82"],["5AAA_A_VGHA9000_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"VAL A 897;ALA A 909;MET A 959;GLY A 962;LEU A1016;ASP A1027","ADP A1200 (-4.4A);ADP A1200 (-3.5A);None;ADP A1200 ( 4.0A);ADP A1200 (-4.7A);ADP A1200 (-3.4A)","0.39A","5aaaA-5lpzA:23.4","5aaaA-5lpzA:26.45"],["5AAA_A_VGHA9000_1","5td2","Homo sapiens","TYROSINE-PROTEIN KINASE MER","PF07714(Pkinase_Tyr)",7,"LEU A 593;VAL A 601;ALA A 617;LEU A 671;MET A 674;GLY A 677;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.50A","5aaaA-5td2A:12.8","5aaaA-5td2A:38.05"],["5AAA_A_VGHA9000_1","5tur","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-1","no annotation",6,"LEU A  44;VAL A  52;ALA A  65;LEU A 120;LEU A 174;ASP A 186","None;7LK A 401 (-4.9A);7LK A 401 (-3.3A);7LK A 401 (-4.0A);7LK A 401 (-4.8A);None","0.85A","5aaaA-5turA:21.8","5aaaA-5turA:22.95"],["5AAA_A_VGHA9000_1","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",7,"LEU A 542;VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.51A","5aaaA-5u6bA:30.6","5aaaA-5u6bA:40.98"],["5AAA_A_VGHA9000_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"VAL A 106;ALA A 119;MET A 172;GLY A 175;LEU A 221;ASP A 232","None","0.64A","5aaaA-5u7qA:20.9","5aaaA-5u7qA:23.98"],["5AAA_A_VGHA9000_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",6,"VAL A 205;ALA A 218;LEU A 271;MET A 274;LEU A 324;ASP A 335","QRW A 601 (-4.7A);QRW A 601 (-3.4A);QRW A 601 ( 4.9A);MES A 604 (-3.9A);None;QRW A 601 (-3.7A)","0.84A","5aaaA-5uuuA:22.6","5aaaA-5uuuA:23.38"],["5AAA_A_VGHA9000_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"LEU A  24;VAL A  32;ALA A  45;MET A  98;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.62A","5aaaA-5w5jA:9.5","5aaaA-5w5jA:27.53"],["5AAA_A_VGHA9000_1","5wnm","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 4","no annotation",6,"VAL A  36;ALA A  49;MET A  99;GLY A 102;LEU A 150;ASP A 161","VX6 A 402 (-4.6A);VX6 A 402 (-3.2A);None;VX6 A 402 (-3.5A);VX6 A 402 (-4.4A);VX6 A 402 (-4.3A)","0.50A","5aaaA-5wnmA:28.2","5aaaA-5wnmA:15.90"],["5AAA_A_VGHA9000_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;ALA A 906;GLY A 962;LEU A1010;GLY A1020;ASP A1021","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);ADP A1201 ( 4.1A);ADP A1201 (-4.5A);None; MG A1203 (-1.8A)","0.63A","5aaaA-6c7yA:29.1","5aaaA-6c7yA:15.97"],["5AAA_A_VGHA9000_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",7,"LEU A 197;VAL A 205;ALA A 217;MET A 267;GLY A 270;LEU A 319;GLY A 329","FKY A9001 (-4.1A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);None;FKY A9001 (-3.3A);FKY A9001 ( 4.9A);FKY A9001 (-3.4A)","0.89A","5aaaA-6cz4A:30.0","5aaaA-6cz4A:19.12"],["5AAA_A_VGHA9000_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",6,"VAL A 200;ALA A 211;MET A 265;GLY A 268;LEU A 318;ASP A 329","CJT A 502 ( 4.8A);CJT A 502 (-3.4A);CJT A 502 (-4.9A);CJT A 502 ( 4.3A);CJT A 502 (-4.7A);CJT A 502 ( 4.0A)","0.53A","5aaaA-6f3dA:24.5","5aaaA-6f3dA:13.70"],["5AAA_A_VGHA9000_1","6fdy","-","-","no annotation",6,"LEU U  20;VAL U  28;ALA U  42;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.68A","5aaaA-6fdyU:22.2","5aaaA-6fdyU:undetectable"]]